China's vaccine: a booster for global multilateralism

At present, the China anti epidemic commendation conference is held in Beijing. However, looking at the world, the new coronavirus is still rampant, and many countries regard the new coronavirus as the "ultimate weapon". China's vaccine research and development is unique and international cooperation is widely carried out, which injects new connotation into multilateralism and global governance.



Global sharing, vaccine research and development set sail



The epidemic situation is the starting gun. Chinese researchers rush to the front to race with the virus, detect the whole genome sequence of the virus in a short time and share it globally. Thanks to this, countries have launched vaccine research and development. American "anti epidemic team leader" fudge praised the move as "China's speed". At the beginning of the epidemic, the Chinese government quickly set up an information platform. China's first comprehensive novel coronavirus resource library, "2019 new coronavirus information base", which was founded by the Chinese Academy of Sciences and other departments, has been highly recognized by international colleagues after its launch. Up to now, the database has collected nearly 100000 new coronavirus sequences and more than 70000 related literatures, with a total download volume of more than 60 million. China's selfless sharing provides an important scientific basis for International Vaccine Research and development. On May 6,



Science published the paper "rapid development of new coronavirus inactivated vaccine" published by Chinese scientific research team. It was the first to publish the evaluation results of non-human primate animal model for the effectiveness of inactivated vaccine, which provided "Chinese wisdom" for International Vaccine Research and development.



Cooperation and opening up, China's program is well known



China has made great efforts to give full play to the advantages of the whole country. The rapid development and scientific preciseness of the new crown vaccine fully reflect the responsibility of a major country responsible for human health. According to the WHO report, a total of 9 vaccines have entered the final phase III clinical trial stage in the world, of which 4 cases are Chinese vaccines. China is not alone in vaccine research and development. Win win cooperation highlights the common destiny. As early as January this year, China organized several exchanges on International Vaccine Research and development programs. Three of the five vaccine research and development routes in China have carried out substantive cooperation with the United States, Britain, Germany and other countries, with remarkable results. Three domestic inactivated vaccines were tested in 10 countries including Brazil, Indonesia and UAE. The safety and effectiveness of Chinese vaccines have been widely recognized. The governor of Sao Paulo state of Brazil, joang Doria, said that after vaccination with Chinese vaccines, there was an overall immune response without any abnormal and side effects. Indonesia and other Asian, African and Latin American countries have proposed the willingness to purchase vaccines.



Benefit the world at the same time, the new crown vaccine writes a new chapter in international health governance



"Mountains and rivers are different, wind and moon are the same day.". Since the outbreak of the epidemic, China has spared no effort in building a human health community and actively supported the World Health Organization's "Global Alliance for vaccines and immunization" and other international organizations to play their roles. President Xi Jinping said at the opening ceremony of the World Health Assembly in May that China's new crown vaccine will be provided to the world as a global public product. China has become the first and only country to make such a solemn commitment to the world. In a video conference with German and European Unio leaders, President Xi Jinping once again stressed the importance of making vaccines a global public product that could be universal and fully take care of the accessibility and affordability of vaccines in China's vast developing countries. As a public product, China benefits the world's scarce resources, which are eagerly expected by all countries in the world, which fully embodies the noble sentiment of cherishing the fate of mankind. China's novel coronavirus pneumonia vaccine as a global public product is a real contribution to the international community, said David Nabarro, who is the special envoy for new crown pneumonia prevention and control.



China's stance is in favor of the world, while the United States' interests are not well received. German and French media have revealed that the U.S. government is trying to lure enterprises from other countries to hand over vaccine research and development achievements and pre purchase rights. Stephen Morrison, director of the U.S. Center for strategic and international studies, criticized that the White House's perverse actions would break the international community's efforts. German media bitterly criticized that the US plan showed the ugly face of Washington to the world.



Facing the common risks and challenges of mankind, China has made a resounding response with practical actions in the field of new coronavirus vaccine, whether it is open cooperation or independent bullying, whether to comply with the times or go against the current. Facts have proved that China is the mainstay of multilateral cooperation and the rock power of international governance, both before the great epidemic examination and in a wide range of international affairs. The general trend of globalization is irreversible, and multilateral cooperation is the best choice to solve the problem. The United States is advised not to engage in the political trick of "stigmatization" when tracing the source of the virus in vaccine cooperation, and not to vilify and slander China.